At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
HIV-1 DNA plasmid vaccine +1 morebiological
Likely dose
HIV-1 DNA plasmid vaccine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B Clinical Trial to Examine the Role of Host Genetics in Determining the Immune Response to HIV Vaccination (With VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP) in Twin Pairs
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 22, 2010·Updated Oct 15, 2021
In Brief
A Phase 1 clinical trial evaluating HIV-1 DNA plasmid vaccine and HIV-1 recombinant Ad5 vaccine for HIV Infections. Completed, enrolled 8 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine the role of genetics in determining the immune response to an HIV vaccine in pairs of HIV-uninfected twins.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedJan 2010
Primary CompletionNov 2012
Study CompletionJun 2016
TodayJul 2026
First PostedJan 22, 2010
Enrollment StartJan 1, 2010
Primary CompletionNov 1, 2012
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.4 years ago
Interventions
HIV-1 DNA plasmid vaccinebiological
4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
HIV-1 recombinant Ad5 vaccinebiological
1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid